Investor Relations

(Security Code :4506 TSE Prime)

Pick Up

Jun. 26, 2025	Sumitomo Pharma Announces Organizational Realignment	Corporate
Jun. 26, 2025	Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group	Corporate
Jun. 26, 2025	Matters Concerning Controlling Shareholders, Etc.	Corporate
Jun. 13, 2025	Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis（PDF/37KB）	R&D
Jun. 06, 2025	Knight Therapeutics and Sumitomo Pharma enter into Exclusive Licensing Agreements to commercialize Sumitomo’s Canadian Portfolio（PDF/175KB）	Corporate
May 30, 2025	Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Ozempic Subcutaneous Injection, a Treatment for Type 2 Diabetes, in Japan	Licensing

Jul. 31, 2025	1st Quarter of FY2025 financial results announcement (planned, 3:30 p.m.)